$504.6 M

ZOM Mkt cap, 22-Sept-2021

$14.1 K

Zomedica Pharmaceuticals Revenue Q1, 2021
Zomedica Pharmaceuticals Gross profit (Q1, 2021)8.5 K
Zomedica Pharmaceuticals Gross profit margin (Q1, 2021), %59.9%
Zomedica Pharmaceuticals Net income (Q1, 2021)-4 M
Zomedica Pharmaceuticals EBIT (Q1, 2021)-3.9 M
Zomedica Pharmaceuticals Cash, 31-Mar-2021276.6 M
Zomedica Pharmaceuticals EV229 M
Get notified regarding key financial metrics and revenue changes at Zomedica PharmaceuticalsLearn more
Banner background

Zomedica Pharmaceuticals Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018

R&D expense

1.5m2.8m10.3m

General and administrative expense

2.9m3.9m4.5m

Operating expense total

4.4m6.7m14.8m

Depreciation and amortization

45.8k92.4k205.8k

EBIT

(5.7m)(8.1m)16.6m

Pre tax profit

(8.1m)(16.6m)

Net Income

(5.7m)(8.1m)(16.6m)

Quarterly

USDQ3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

14.1k

Cost of goods sold

5.7k

Gross profit

8.5k

Gross profit Margin, %

60%

R&D expense

630.4k7.5m1.1m962.5k630.1k3.9m413.1k

General and administrative expense

834.6k3.2m921.4k1.4m1.2m988.7k3.5m

Operating expense total

1.5m10.8m2.0m2.4m1.9m4.9m3.9m

EBIT

(1.8m)(11.7m)(2.4m)(2.8m)(2.3m)(5.3m)(3.9m)

EBIT margin, %

(27417%)

Interest expense

6.2k12.2k12.2k651.0

Interest income

5.5k247.055.1k

Pre tax profit

(1.9m)(11.7m)(2.4m)(2.8m)(2.5m)(5.3m)(4.0m)

Net Income

(1.9m)(11.7m)(2.4m)(2.8m)(2.5m)(5.3m)(4.0m)

Zomedica Pharmaceuticals Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

3.2m3.4m1.9m510.6k62.0m

Accounts Receivable

18.9k28.3k53.7k67.6k146.2k

Prepaid Expenses

332.6k786.3k

Current Assets

3.6m4.3m3.9m1.8m62.9m

PP&E

289.0k371.2k717.1k729.1k583.0k

Total Assets

4.6m5.2m6.0m4.2m66.1m

Accounts Payable

734.4k828.7k2.4m2.1m1.2m

Short-term debt

6.7k780.1k

Current Liabilities

741.2k828.7k2.4m2.1m2.0m

Long-term debt

1.6m

Non-Current Liabilities

1.1m

Total Debt

6.7k2.4m

Total Liabilities

3.1m

Common Stock

10.2m18.2m30.4m38.6m104.8m

Preferred Stock

12.0m

Additional Paid-in Capital

1.2m1.8m1.2m3.6m14.8m

Retained Earnings

(7.6m)(15.6m)(32.3m)(52.1m)(69.0m)

Total Equity

3.8m4.4m3.7m2.1m51.1m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.2 x1.2 x1.6 x2 x1.3 x

Zomedica Pharmaceuticals Cash Flow

Annual

USDFY, 2017FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(5.7m)(8.1m)(16.6m)(19.8m)(16.9m)

Depreciation and Amortization

45.8k92.4k205.8k1.1k181.7k

Accounts Receivable

(21.0k)(9.4k)(25.4k)(14.0k)(78.6k)

Accounts Payable

552.6k94.3k1.5m(289.0k)(838.9k)

Cash From Operating Activities

(4.6m)(7.1m)(11.1m)(15.6m)(16.2m)

Purchases of PP&E

(231.6k)(171.7k)(628.0k)(155.5k)(14.8k)

Cash From Investing Activities

(241.2k)(171.7k)(619.0k)(686.9k)1.0m

Long-term Borrowings

2.0k(6.7k)

Cash From Financing Activities

4.8m7.5m10.3m14.9m76.7m

Net Change in Cash

(17.0k)221.5k(1.5m)(1.4m)61.5m

Interest Paid

18.3k732.0

Zomedica Pharmaceuticals Ratios

USDFY, 2016

Financial Leverage

1.2 x